STOCK TITAN

Anixa Biosciences Inc - ANIX STOCK NEWS

Welcome to our dedicated news page for Anixa Biosciences (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Anixa Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Anixa Biosciences's position in the market.

Rhea-AI Summary
Anixa Biosciences, Inc. announces dose escalation for fourth patient in Phase 1 clinical trial of CAR-T therapy for ovarian cancer. The trial, in partnership with Moffitt Cancer Center, aims to demonstrate efficacy of FSHR-mediated CAR-T technology in solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
clinical trial
-
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) to present at 2024 NeauxCancer Conference, showcasing innovative cancer treatment approaches using the body's immune system. CEO Dr. Amit Kumar to meet investors and discuss the company's focus on cancer vaccine development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
Rhea-AI Summary
Anixa Biosciences, Inc. has announced that its collaborator, Cleveland Clinic, has received a 'Decision to Grant' notice from the Japan Patent Office for the patent application titled 'Ovarian Cancer Vaccines.' The patent extends the claims for this novel ovarian cancer vaccine technology to Japan, joining the European and U.S. patents awarded last year. Anixa is the exclusive worldwide licensee of the technology, which has shown promising results in pre-clinical studies. The vaccine has the potential to provide safe and effective preemptive immunity against epithelial ovarian carcinoma, the most common form of ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) to Present Business and Clinical Programs at Sidoti Micro-Cap Virtual Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.11%
Tags
conferences
-
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) to present business overview and clinical program updates at Biotech Showcase and J.P. Morgan Healthcare Conference 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
conferences
-
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) announced positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial, conducted in collaboration with Cleveland Clinic and funded by a U.S. Department of Defense grant, showed increased T cell immune response indicators and antibody production. The majority of patients developed antigen-specific T cell responses, and the vaccine was safe and well tolerated. Anixa plans to investigate additional dose levels and continue studying the vaccine's safety and immunologic effects in two additional patient cohorts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.4%
Tags
clinical trial
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) to Release New Data from Ongoing Phase 1 Clinical Trial of Breast Cancer Vaccine at 2023 SABCS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.4%
Tags
conferences clinical trial
-
Rhea-AI Summary
Anixa Biosciences (ANIX) announced that its partner, Cleveland Clinic, has received an 'Intention to Grant' notice from the European Patent Office for the patent application titled 'Ovarian Cancer Vaccines.' The patent targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED) and is a significant development in the treatment and prevention of ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
none
-
Rhea-AI Summary
Anixa Biosciences, Inc. will present at the Ovarian Cancer National Conference to discuss the clinical development of its Phase 1 ovarian cancer CAR-T therapy. The conference is organized by the Ovarian Cancer Research Alliance, which has invested $100 million in research and advocated for $200 million in government funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
conferences
Rhea-AI Summary
Anixa Biosciences completes treatment of first patient cohort in ovarian cancer clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
clinical trial
Anixa Biosciences Inc

Nasdaq:ANIX

ANIX Rankings

ANIX Stock Data

122.41M
30.19M
4.6%
14%
2.15%
Computer Storage Device Manufacturing
Manufacturing
Link
US
San Jose

About ANIX

itus develops and acquires patented technologies for the purposes of patent monetization and patent assertion. the company currently has 8 patent portfolios in the areas of key based web conferencing encryption, encrypted cellular communications, nano field emission display (“nfed”), micro electro mechanical systems display (“mems”), j-channel window frame construction, vpn multicast communications, internet telephonic gateway, and enhanced auction technologies. itus’s management team has over 30 years of combined experience in patent monetization and patent assertion, and has generated in excess of $150 million patent licensing revenues